Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06924970 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)
A Phase 2 study of Sickle Cell Disease, sponsored by Agios Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT06924970 is a Phase 2 study of Sickle Cell Disease that is actively recruiting participants, run by Agios Pharmaceuticals. The registered enrollment target is 56 participants, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (81% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT06924970, a Phase 2 study of Sickle Cell Disease, is actively recruiting participants, sponsored by Agios Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
Conditions Studied
Interventions
- DRUG Tebapivat
- DRUG Tebapivat Matched Placebo
Study Locations (20)
District of Columbia
- Children's National Hospital - Washington D.C.
- MedStar Washington Hospital Center - Washington D.C.
Michigan
- Henry Ford Health System - Detroit
- Children's Hospital of Michigan - Detroit
New York
- Icahn School of Medicine at Mt. Sinai - New York
- Montefiore Medical Center - The Bronx
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
- University of Pittsburgh Medical Center - Pittsburgh
Wallonne
- CHR de la Citadelle - Liège
- Clinique CHC MontLégia - Liège
Colorado
- UCHealth at University of Colorado Anschutz Medical Campus - Aurora
Connecticut
- UConn Health - Farmington
Georgia
- Emory-Children's Center/ Children's Healthcare of Atlanta: Arthur M. Blank Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-05-01 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06924970
The ClinicalTrials.gov registry entry for NCT06924970 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 293-participant average among 213 other Sickle Cell Disease trials with a reported enrollment target (81% lower). The listed sponsor is Agios Pharmaceuticals, which has 44 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sickle Cell Disease appearing as the primary indexed condition, and to 2 interventions - of which Tebapivat is the first listed.
NCT06924970 reports 20 study locations spanning 15 distinct geographic areas - top geographies include District of Columbia, Michigan, New York.
Frequently Asked Questions
What is clinical trial NCT06924970 about?
NCT06924970 is a clinical study titled "A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)". The main purpose of this study is to compare the effect of tebapivat versus placebo on anemia and to detect a dose-response for hemoglobin (Hb) response in participants with SCD.
What is the current status of trial NCT06924970?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-05-01. Estimated completion is 2027-05.
What conditions does trial NCT06924970 study?
This clinical trial studies the following conditions: Sickle Cell Disease.
What interventions are being tested in trial NCT06924970?
The interventions under investigation include: Tebapivat (DRUG), Tebapivat Matched Placebo (DRUG).
Who is sponsoring clinical trial NCT06924970?
This trial is sponsored by Agios Pharmaceuticals, which has 44 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06924970 being conducted?
This trial has 20 study locations across Colorado, Connecticut, District of Columbia, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Sickle Cell Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults
RECRUITING · Phase 2
-
Relationship Between Abnormal Myocardial Perfusion and Diastolic Dysfunction in Sickle Cell Disease Using PET
RECRUITING · Phase 2
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
RECRUITING · Phase 2
-
A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)
RECRUITING · Phase 2
-
A Phase 2/3 Study in Adult and Adolescent Participants With SCD
RECRUITING · Phase 2
-
Allo HSCT for High Risk Hemoglobinopathies
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.